scholarly journals Construction of a Suite of Computable Biological Network Models Focused on Mucociliary Clearance in the Respiratory Tract

2019 ◽  
Vol 10 ◽  
Author(s):  
Hasmik Yepiskoposyan ◽  
Marja Talikka ◽  
Stefano Vavassori ◽  
Florian Martin ◽  
Alain Sewer ◽  
...  
1997 ◽  
Vol 83 (4) ◽  
pp. 1348-1359 ◽  
Author(s):  
Scot L. Winters ◽  
Donovan B. Yeates

Winters, Scot L., and Donovan B. Yeates. Interaction between ion transporters and the mucociliary transport system in dog and baboon. J. Appl. Physiol. 83(4): 1348–1359, 1997.—To gain insight into the role of epithelial ion channels, pumps, and cotransporters in regulating airway water and mucociliary transport, we administered inhibitors of the Na+ channel (amiloride), 3Na-2K-adenosinetriphosphatase (acetylstrophanthidin), and Na-K-2Cl cotransporter (furosemide) to anesthetized dogs and/or baboons. Tracheal ciliary beat frequency was measured by using heterodyne laser light scattering. Tracheal mucus velocity (TMV) and bronchial mucociliary clearance (BMC) or lung mucociliary clearance were measured by using radioaerosols and nuclear imaging. Respiratory tract fluid output was collected by using a secretion-collecting endotracheal tube. In six dogs, amiloride aerosol [lung deposition, 96 ± 11 μg (means ± SE)] had minimal effect, whereas acetylstrophanthidin aerosol (lung deposition, 71 ± 9 μg) increased BMC, and furosemide (40 mg iv) markedly increased TMV. In five baboons, TMV increased after iv furosemide administration (2 mg/kg) as well as by aerosol (lung deposition, 20 ± 3 mg), coincident with increases in ciliary-mucus coupling from 11.5 ± 0.1 to 29.5 ± 0.4 and 46.5 ± 0.7 μm/beat, respectively. Furosemide also increased lung mucociliary clearance in baboons. In dogs, respiratory tract fluid output increased after intravenous furosemide from 2.2 ± 0.5 to 6.8 ± 1.7 mg/min. When combined with dry-air inhalation, furosemide failed to stimulate TMV and reversed the inhibition of BMC by dry air. Thus pharmacological manipulation of the Na-K-2Cl cotransporter and the 3Na-2K-adenosinetriphosphatase pump may provide increases of clinical relevance in airway hydration and mucociliary transport.


1994 ◽  
Vol 87 (5) ◽  
pp. 639-644
Author(s):  
Michihiro NOSE ◽  
Junichi YOSIDA ◽  
Junji ONO ◽  
Hiroshi KIKUMORI ◽  
Morihiro IRIFUNE ◽  
...  

2012 ◽  
Vol 29 (4) ◽  
pp. 350-358 ◽  
Author(s):  
Frank Begrow ◽  
Corinna Böckenholt ◽  
Martina Ehmen ◽  
Thomas Wittig ◽  
Eugen J. Verspohl

2021 ◽  
pp. 78-84
Author(s):  
A. R. Denisova ◽  
N. G. Kolosova ◽  
I. V. Grebeneva ◽  
V. D. Denisova ◽  
M. V. Glukhova ◽  
...  

Introduction. Cough is the most common manifestation of respiratory infections of the upper and lower respiratory tract and indicates impaired mucociliary clearance. The cause of cough must be determined to choose the management tactics for children with cough. The most commonly used mucoactive drugs liquefy sputum as a result of a direct action of the components on the tracheobronchial secretion and/or mucosa of the respiratory tract. Given the mucoactive effect of hypertonic salines, we conducted an open clinical study of the effectiveness of 3% hypertonic saline with hyaluronic acid in acute bronchitis in children.Aim of the study. To evaluate the clinical effect of 3% hypertonic saline with hyaluronic acid in acute bronchitis in children.Materials and methods. Clinical efficacy and safety of 3% hypertonic saline with hyaluronic acid in 50 patients aged 3 to 12 years old with acute bronchitis were evaluated in the dynamics on the 1st, 3rd, 7th days of treatment with the score assessment of symptoms (cough, stuffy nose, auscultation data) and an indication of adverse events (if any).Results. Improvement of condition was noted in most patients by the 3rd day of therapy (mean score 1.88 ± 0.3), temperature normalized in all patients, manifestations of rhinitis decreased. By the 5th day of treatment, the intensity of cough did not exceed 1 point in all patients (0.7 ± 0.14 points). According to the patient’s diary data, by the 7th day of treatment 74% of the children had no cough. On the 7th day of treatment, some children had a rare residual cough (0.36 ± 0.06 points), minor rhinitis (0.16 ± 0.1 points). No rales were heard in the lungs in all patients, rigid breathing was heard in 11 patients (mean score 0.22 ± 0.05).Conclusions. The conducted study demonstrated that 3% hypertonic saline with hyaluronic acid is an effective drug in the treatment of cough in acute bronchitis in children.


2021 ◽  
pp. 29-34
Author(s):  
A. V. Gurov ◽  
M. A. Yushkina

Purulent-inflammatory diseases of the upper respiratory tract and ENT organs are an urgent problem of modern clinical medicine. The high prevalence of this pathology is due to the active effect of pathogenic microflora on the mucous membrane of the respiratory tract, the increasing role of opportunistic and atypical microorganisms in the genesis of infection of the upper respiratory tract, as well as disorders in the mucociliary clearance. Limitations in the mobility of cilia of ciliated cells, as well as their partial or complete absence, a change in the composition of mucous secretions and a slowdown in the speed of mucus movement are the mechanisms that determine the possibility of an acute inflammation focus on the mucous membrane of the upper respiratory tract, and also increase the risk of developing chronic inflammatory diseases of the ENT organs. The accumulated data on the peculiarities of the existence of microbial biocenoses in the human body, as well as the steady widespread growth of the problem of antibiotic resistance, dictate the need to search for new solutions in the treatment of purulent-inflammatory pathology of the ENT organs. A well-established principle of therapy for such conditions is the topical use of combined drugs that combine mucolytic and antibacterial components that actively affect the main links in the pathogenesis of acute and chronic inflammation of the upper respiratory tract. These tasks are most effectively solved by the drug, which contains the mucolytic N-acetylcysteine, which potentiates the effect of another component – the antibiotic thiamphenicol. An important aspect in favor of choosing this drug as a monotherapy or combination therapy for purulent-inflammatory diseases of the upper respiratory tract is a convenient form of release for aerosol administration.


Sign in / Sign up

Export Citation Format

Share Document